Accelerated Enrollment Solutions

The decision makers in Accelerated Enrollment Solutions are Agata Kurzawa-dobek, Amy Salzl, Anna Kozaczuk, etc. Click to Find Accelerated Enrollment Solutions decision makers emails.

Accelerated Enrollment Solutions (AES) provides a comprehensive range of services designed to support biopharmaceutical companies throughout the clinical trial process. Key services include patient recruitment, feasibility assessments, patient engagement strategies, and study start-up support. AES leverages a global site network to enhance patient enrollment and retention, ensuring that clinical trials are conducted efficiently and effectively.

AES employs a multi-faceted approach to enhance patient recruitment. This includes utilizing advanced analytics to identify suitable patient populations, engaging with patients through targeted outreach and education, and leveraging a global network of clinical trial sites. By focusing on patient-centric strategies, AES aims to streamline the recruitment process and reduce time to enrollment, ultimately leading to faster trial completion.

AES primarily supports the biopharmaceutical industry, including companies involved in drug development across various therapeutic areas. This includes pharmaceuticals, biotechnology, and medical device manufacturers. By providing tailored solutions to meet the unique challenges of each industry, AES helps ensure that clinical trials are conducted successfully and efficiently.

Yes, AES has extensive experience in managing global clinical trials. The company has established a robust global site network that allows for efficient patient recruitment and data collection across multiple countries. AES understands the regulatory and logistical complexities of conducting trials internationally and provides the expertise needed to navigate these challenges, ensuring compliance and successful trial outcomes.

Patient centricity is a core principle of AES's approach to clinical trials. By prioritizing the needs and preferences of patients, AES enhances engagement and retention throughout the trial process. This includes designing studies that are more accessible and convenient for participants, as well as providing clear communication and support. By focusing on the patient experience, AES aims to improve enrollment rates and ensure that trials yield meaningful results.

AES conducts thorough feasibility assessments to evaluate the potential for successful patient recruitment and site performance for clinical trials. This process involves analyzing demographic data, site capabilities, and historical performance metrics. By gathering insights from a variety of sources, AES can provide biopharmaceutical companies with actionable recommendations and a clear understanding of the likelihood of meeting enrollment targets, ultimately aiding in informed decision-making for trial planning.